Our focus – Market

Demand for medication to treat pain related to migraine and breakthrough pain in cancer patients is expected to grow significantly in coming years. The main driving forces for this include increasingly large patient groups combined with new, innovative medications with better, faster effects.

Klaria's business concept is based on developing and commercialising innovative products with clear competitive benefits in the therapeutic fields of migraine and cancer-related pain. In total, the two markets are estimated to exceed sales of USD 7 billion, and a high level of growth is anticipated for the future1. The factors that unite the two therapeutic fields are large – and growing – patient groups, severe pain and extensive demand for medication with more stable effects and more rapid absorption than that offered by existing medications.

1) The Global Market for Pain Management Drugs and Devices, 2013, BCCReseach